Board summary
Key figures
49,807
Registered population
50.5% aged 18–64
33.8%
Aged 65+
ICB 21.9% · England 17.9%
5.6%
Ethnic minority (non-White)
2.0% Asian · England 9.6%
22.1%
In IMD quintile 1
ICB 9.2% · England 21.0%
~7,325
Core20 residents (est.)
Resident basis; registered basis ~11,043 · see page 3
11,368
Hypertension register
+1.97% in 3 yrs · England +5.60%
722
SMI register
64.8% of Rother's
1,611
COPD register
Reviews -2.91% in 3 yrs
Forecast to 2030
12,152
Hypertension patients, 2030
+784 on today
58.3%
QRISK ≥20% on statins, 2030
+1.84pp over 3 yrs
7.8%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma reviews fell behind England.
Annual asthma reviews fell 10.6% over 2023 to 2025 (England +4.4%) to 56.0%, leaving about 1,600 patients unreviewed, which may reflect recall gaps.
Under-80 blood pressure and lipid gaps.
Under-80 BP control is 61.5% (England 67.8%) and lipid therapy in QRISK ≥ 20% is 54.4% (England 63.6%), which could reflect escalation gaps.
Strong SMI physical health check delivery.
On the SMI register, 87.7% had a blood pressure check (England 83.4%) and 87.2% had BMI recorded (+11.4 pp over 2023 to 2025).
Population, age and ethnicity
Adults aged 65+ make up 33.8% of registered patients across the PCN
Across three practices, the PCN registers 49,807 patients. Adults aged 65+ comprise 33.8% (16,811 patients), exceeding Rother (30.4%), NHS Sussex Integrated Care Board (21.9%), and England (17.9%). Working-age adults (18-64) represent 50.5% (Rother 53.6%, ICB 60.5%, England 62.7%), while children (0-17) account for 15.8% (Rother 16.1%, ICB 17.7%, England 19.6%). In associated Census areas, 94.4% of usual residents are White (Rother 95.6%, ICB 91.0%, England 81.1%), leaving a 5.6% ethnic minority share. Age groups use GP registrations, whereas ethnicity reflects resident Census data.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Rother local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Rother LA) | 2,294 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.0% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 62.1% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Rother LA) | 1,159 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Rother LA) | 8.4 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation averages 22.1% across the PCN but reaches 38.6% at Sidley Medical Practice
The PCN Core20 cohort is 22.1%, above Rother (13.8%), NHS Sussex Integrated Care Board (9.2%), and England (21.0%). Deprivation concentrates at Sidley Medical Practice (38.6%, estimated 5,062 patients), whereas Collington Surgery has 19.5% (3,198) and Little Common Surgery 13.7% (2,783). Practice estimates sum to 11,043 registered patients, while the resident decile 1 and 2 estimate is 7,325, resting on different denominator bases.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
722
SMI register
1.44% recorded prevalence
377
Learning disability register
0.75% recorded prevalence
46
Care homes, 1,437 beds
In the PCN catchment
9.9%
Provide unpaid care
Rother, Census 2021
Recorded prevalence is 1.4% for severe mental illness (722 patients) and 0.8% for learning disability (377 patients), both exceeding Rother (1.2% and 0.7%), NHS Sussex Integrated Care Board (1.1% and 0.6%), and England (1.0% and 0.6%). The catchment includes 46 care homes with 1,437 beds.
Severe mental illness: physical health checks
SMI prevalence is 1.4% (England 1.0%). Published checks exceed England: blood pressure reached 87.7% (England 83.4%), BMI recording 87.2% (England 82.1%), and alcohol status 86.1% (England 81.8%). Missing health-check elements were not captured and cannot be assumed complete.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
11,368
Hypertension register
+1.97%
Register growth, 3 yrs
Rother +3.70% · England +5.60%
−0.33pp
BP control, under 80
≤140/90 · +0.80pp aged 80+
+784
More patients by 2030
Forecast 12,152 (23.64%)
Hypertension case-finding and control
The PCN records 11,368 patients on the hypertension register (22.7% crude prevalence, versus Rother 22.0%, NHS Sussex Integrated Care Board 16.3%, and England 15.2%). While 88.7% have a recent blood pressure reading (England 90.0%), control under 80 years is 61.5%, below Rother (64.8%), the ICB (66.8%), and England (67.8%), after falling 0.5% over 2023 to 2025 (England +3.2%). By practice, control is 57.6% at Collington Surgery, 64.0% at Sidley Medical Practice, and 63.4% at Little Common Surgery. Blood pressure control under 80 lags regional and national benchmarks, indicating that structured recall and titration could be prioritised.
Lipids and statins
Lipid-lowering therapy uptake is 54.4% in patients with QRISK ≥ 20% and 61.6% in CKD, trailing England (63.6% and 70.3%) and NHS Sussex Integrated Care Board (60.0% and 65.9%). Denominators include personalised care adjustments. Fewer at-risk patients receive lipid-lowering therapy than national rates imply, indicating that systematic recall audits could be prioritised.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 97,318 | £2.60 | £2.42 | £1.86 | £253,027 |
| Cardiovascular (all), 2025 | 137,203 | £3.56 | £3.32 | £3.33 | £488,443 |
For lipid-modifying drugs in 2026, the PCN prescribed 97,318 items at £2.60 per item, exceeding England (£1.86) and NHS Sussex Integrated Care Board (£2.42), but below Rother (£2.78), spending £72,015 more than at England's unit cost. Higher unit costs alongside lower uptake suggest an opportunity to review lipid-modifying formulary choices without restricting appropriate therapy.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−10.63%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.90%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.4% (3,560 patients), above England (6.6%). Over 2023 to 2025, asthma reviews fell 10.6% (England +4.4%) to 56.0% (England 65.7%), leaving about 1,600 unreviewed patients. Paediatric asthma prescribing reached 2,475 rate per 1000 aged 5-19 (England 1,488 rate). COPD prevalence is 3.2% (1,611 patients; England 1.9%), with reviews falling 2.9% (England +2.8%) to 78.4% (England 76.4%). Slower review delivery alongside heavy prescribing may reflect recall constraints, unverified locally.
Cancer register and children's immunisation
Cancer prevalence is 6.7% (3,330 patients), above England (3.8%) and NHS Sussex Integrated Care Board (4.7%). In childhood immunisation (Q1 2025/26), 6-in-1 coverage at 12 months reached 92.0% (3 pp below the 95.0% target). At age five, MMR first-dose coverage was 87.3% and second-dose coverage was 84.8% (a 2.5 pp dose difference and 10.2 pp below target). These age-cohort contrasts could reflect access barriers, although denominators are small.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In 2022, 58.5% of cancers with a known stage in NHS Sussex ICB were diagnosed at stage 1 or 2 (4,799 of 8,209 staged cases), above England (55.3%) but below the 75.0% national ambition by 2028 by 16.5 pp. Staging was known for 64.3% of 12,766 registered cancers. Reaching 75.0% requires about 1,360 additional early-stage cases annually across the ICB. ICB early-stage share increased 5 pp between 2013 and 2022. For Bexhill PCN, 3-year cancer prevalence change was +8.4% (2023 to 2025; England +9.0%, Rother +9.9%), with Collington Surgery recording +6.1%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), East Sussex Healthcare NHS Trust achieved 84.2% on the 28-day faster diagnosis standard (standard 75.0%) and 98.2% on the 31-day treatment standard (standard 96.0%), but 67.0% on the 62-day referral-to-treatment standard, below the 85.0% standard by 18.0 pp. This trailed NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%). For diagnostics, 5.3% waited 6+ weeks at the trust (England 23.1%). These provider measures describe wider acute activity, not PCN performance.
| Pathways within standard (%) | East Sussex Healthcare | Maidstone and Tunbridge Wells | Sussex | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 84.20 | 81.78 | 74.01 | 79.29 | 79.32 |
| 31-day treatment (96%) | 98.19 | 98.35 | 76.79 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 67.04 | 87.43 | 65.20 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Sussex Healthcare | Maidstone and Tunbridge Wells | Sussex | England |
|---|---|---|---|---|
| MRI | 6.48 | 0.92 | 5.62 | 21.40 |
| CT | 0.48 | 0.51 | 8.57 | 9.92 |
| Echocardiography | 21.94 | 2.57 | 0.39 | 28.48 |
| Colonoscopy | 0.74 | 19.80 | 39.35 | 30.83 |
| Gastroscopy | 0.31 | 24.03 | 20.02 | 29.02 |
| All 15 DM01 tests | 5.27 | 6.42 | 12.95 | 23.14 |
| Community services activity | East Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 100,740 | 309,615 |
| Referrals | 17,285 | 66,930 |
| Patients with a contact | 25,880 | 85,660 |
Community services (residents of East Sussex), Jun 2026 (provisional). In Jun 2026 (provisional), East Sussex recorded 105,045 community care activities and 100,740 care contacts across 25,880 patients, with adults aged 65+ accounting for 68% of contacts. Across NHS Surrey and Sussex Integrated Care Board, community activity totalled 316,320 care activities and 309,615 care contacts. These figures represent submitted experimental activity for residents and the wider system rather than unique Bexhill PCN patients.
Practice variation and patient experience
Practice variation and patient experience
Clinical QOF domain achievement reached 100.0% at Collington Surgery, 98.2% at Sidley Medical Practice, and 95.9% at Little Common Surgery (England 97.1%). Vaccination and immunisation achievement spans a 49.3 pp range: Little Common Surgery reached 64.9%, Collington Surgery recorded 48.4%, and Sidley Medical Practice attained 15.6% (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Little Common | 120 | 13.7 | 54.5% | 64.8% | 74.6% |
| Collington Surgery | 99 | 19.5 | 26.0% | 60.8% | 58.7% |
| Sidley Medical | 116 | 38.6 | 25.6% | 47.4% | 53.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fourteen of 25 tracked three-year trends trail England, led by asthma review declines
Across 25 tracked measures, 14 three-year trends trail England. Over 2023 to 2025, the widest lags are in reviews and blood pressure control: asthma review change was -10.6% (England +4.4%), COPD reviews were -2.9% (England +2.8%), and under-80 blood pressure control was -0.5% (England +3.2%). Conversely, heart failure reviews rose +13.3% (England +8.7%) to 80.0%, and severe mental illness checks improved, with body mass index recording up +11.4 pp (England +5.1 pp) and alcohol checks up +10.2 pp (England +5.4 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
COPD reviews
Learning disability register
BP control, under 80
Hypertension register
BMI record (SMI)
Alcohol record (psychosis)
Heart failure reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Rother | Asset | PCN | Rother |
|---|---|---|---|---|---|
| Care homes (catchment) | 46 (1,437 beds) | n/a | Schools (catchment) | 32 | n/a |
| Children's centres | 1 | 2 | Places of worship | 41 | 103 |
| Libraries | 1 | 3 | Food banks (VCS) | 1 | 3 |
| Homelessness support (VCS) | 2 | 2 | Day centres (VCS) | 4 | 26 |
| Children and young people (VCS) | 1 | 6 | Primary schools (LA maintained) | 4 | 23 |
| Primary academies | 6 | 9 | Special schools | 1 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Asthma review coverage is 56.0% (Rother 59.1%, ICB 62.5%, England 65.7%) after falling 10.6% over 2023 to 2025 (England +4.4%), leaving 1,566 (about 1,600) of 3,560 patients unreviewed. For discussion: practices could run a standardised recall search, offer flexible review slots, and combine inhaler prescribing checks with structured annual reviews. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Under-80 hypertension titration recall
Under-80 BP control is 61.5%, below Rother (64.8%), ICB (66.8%), and England (67.8%) by 6.4 pp, falling 0.5% over 2023 to 2025 (England +3.2%) across 11,368 hypertension patients. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
High-risk lipid therapy review
Lipid-lowering therapy covers 54.4% in QRISK ≥ 20% (Rother 57.0%, ICB 60.0%, England 63.6%; 9.1 pp below England) and 61.6% in CKD (England 70.3%), at £2.60 per item (England £1.86). Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult service adaptation (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Core20 denominator reconciliation and targeting (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Hypertension control audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood immunisation catch-up clinics (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer register coding audit (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Core20 cohort (IMD quintile 1) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Under-80 hypertension titration recall (p12) | Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · High-risk lipid therapy review (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy · Patients with diabetes (40+ yrs no history of CVD) treated with a statin (denominator incl. PCAs) | NHS Long Term Plan (diabetes) and National Diabetes Audit | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
